Featured
Splint Invest Secures 500,000 Swiss Francs in “The Lion’s Den”
With the Splint Invest app, the startup makes it possible to diversify one’s portfolio with alternative investments, starting with very small contributions. The platform tokenizes physical assets and then offers the so-called “splints” for purchase so that investors can become co-owners for as little as 50 francs. Investments can be made in whiskey, wine, watches, and other luxury goods, among others.
The Zug-based fintech startup Splint Invest was able to secure an investment of $528,000 (CHF 500,000) in the Swiss edition of “The Lion’s Den” (“Die Höhle der Löwen”). With the app of the same name, the team around Solothurn-based founders Mario von Bergen, Robin Muster, and Aurelio Perucca make it possible to diversify one’s own portfolio with alternative investments such as watches, wine, whiskey, or other luxury goods, starting with very small contributions.
The newly acquired capital will be used, among other things, for the expansion into the DACH region, the expansion of the team, and the development of new asset classes. The company is also currently planning the launch of a secondary market.
In the most recent episode of the Swiss edition of “Die Höhle der Löwen” (The Lion’s Den), the company of the three Solothurn founders Mario von Bergen, Robin Muster, and Aurelio Perucca was able to convince no less than three lions: together, Jürg Schwarzenbach, Lukas Speiser, and Patrick Mollet invest 500,000 Swiss francs in Splint Invest. The episode was filmed in March 2022.
If you want to read more about Splint Invest and its latest investment in the Lion’s Den, download for free our companion app. The Born2Invest mobile app keeps its readers up to date with the latest business news of the day.
Expansion of investment opportunities and expansion into the entire DACH region
In recent months, the startup has already been able to use part of the capital gained to expand its investment opportunities and to expand and diversify its team. With success: the investment platform for alternative investments has already gained 5,000 additional users since the show was filmed.
The remaining capital will now be used to tap into new asset classes and expand into the DACH region. The company also plans to launch a secondary market where shares held can be offered and sold ahead of time by their users. “The 500,000 Swiss francs have enabled us to grow strongly and to significantly professionalize the appearance of Splint Invest. In addition, we may benefit from the wealth of experience and the network of our investors, which makes us immensely happy,” explains Aurelio Perucca, CEO of Splint Invest.
Investment platform for alternative investments
With the Splint Invest app, the startup makes it possible to diversify one’s portfolio with alternative investments, starting with very small contributions. The platform tokenizes physical assets and then offers the so-called “splints” for purchase so that investors can become co-owners for as little as 50 francs. Investments can be made in whiskey, wine, watches, and other luxury goods, among others, which historically not only have a low-risk profile but have also proven to be stable in value.
At the same time, the value of physical assets does not correlate with equity markets, which has historically allowed them to perform well during volatile times. By providing alternative investments at micro amounts, the young founders aim to democratize access to such investments and empower individual investors.
__
(Featured image by henry911 via Pixabay)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in moneycab, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
-
Biotech1 week ago
Laminar Pharma Raises 5.9 Million in a New Round of Financing
-
Crypto11 hours ago
Bitcoin ETF Options Debut in the U.S.: Is a New All-Time High on the Horizon?
-
Biotech2 weeks ago
Leitat Purchases ReadyCell through MedTech Innovation on Advanced Medicine
-
Fintech6 days ago
Metadev3 Now Becomes a Validator on Tezos